Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06732401 · ClinicalTrials.gov registry record · Phase 3
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT06732401: Active Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT06732401 is a Phase 3 study that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 630 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06732401, a Phase 3 study, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Durvalumab
- PROCEDURE Echocardiography Test
- DRUG Ceralasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06732401
The ClinicalTrials.gov registry entry for NCT06732401 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06732401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06732401 about?
NCT06732401 is a clinical study titled "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer". This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking so...
What is the current status of trial NCT06732401?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2025-08-07. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT06732401?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Durvalumab (BIOLOGICAL), Echocardiography Test (PROCEDURE), Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT06732401?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.